China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026)

China Pharma Holdings has reported Cash & Equivalents for 17 years, with the latest figure at $168474.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 59.18% year-over-year to $168474.0; the trailing twelve-month figure through Mar 2026 stood at $168474.0 (down 59.18% YoY), and the FY2025 full-year result was $345112.0, down 44.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $168474.0, down from $345112.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $3.7 million in Q1 2022, with the low at $168474.0 in Q1 2026.
• Historically, Cash & Equivalents has averaged $1.2 million across 5 years, with a median of $838881.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 640.0% — and 2023, when it tumbled 68.46%.
• China Pharma Holdings' Cash & Equivalents stood at $2.0 million in 2022, then fell by 29.86% to $1.4 million in 2023, then slumped by 55.97% to $626879.0 in 2024, then slumped by 44.95% to $345112.0 in 2025, then plunged by 51.18% to $168474.0 in 2026.
• The last three Cash & Equivalents figures came in at $168474.0 (Q1 2026), $345112.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.